Laboratory of Applied Pharmacokinetics and Bioinformatics
Optimizing drug therapy for populations and individuals

Articles

2016

  1. Huurneman, L. J; Neely, M.; Veringa, A.; P'erez, F. D.; Ramos-Martin, V.; Tissing, W. J; Alffenaar, J-W. C and Hope, W. Pharmacodynamics of Voriconazole in Children: Further Steps Along the Path to True Individualized Therapy. In Antimicrobial Agents and Chemotherapy: AAC.03023-15, 2016. doi 
  2. Billat, P-A.; Woillard, J-B.; Essig, M.; Sauvage, F. c-L.; Picard, N.; Alain, S.; Neely, M.; Marquet, P. and Saint-Marcoux, F. Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. In Journal of Antimicrobial Chemotherapy, 71 (2): 484-489, 2016. doi 
  3. Rhodes, N. J; Kuti, J. L; Nicolau, D. P; Neely, M. N; Nicasio, A. M and Scheetz, M. H An exploratory analysis of the ability of a cefepime trough concentration greater than 22~mg/L to predict neurotoxicity. In Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy, 22 (2): 78-83, 2016. doi 
  4. Neely, M.; Philippe, M.; Rushing, T.; Fu, X.; Van Guilder, M.; Bayard, D.; Schumitzky, A.; Bleyzac, N. and Goutelle, S. Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software. In Therapeutic drug monitoring: 1, 2016. doi 
  5. Picard, N; Alain, S and Neely, M Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. In Journal of ldots, 2016.
  6. Rhodes, N J; Kuti, J L; Nicolau, D P and Neely, M N An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. In Journal of Infection and ldots, 2016.

2015

  1. Storset, E.; AAsberg, A.; Skauby, M.; Neely, M.; Bergan, S.; Bremer, S. and Midtvedt, K. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. In Transplantation, 99 (10): 2158-2166, 2015. doi 
  2. Kryshchenko, A.; Schumitzky, A.; van Guilder, M. and Neely, M. Nonparametric estimation of a mixing distribution for a family of linear stochastic dynamical systems. In arXiv.org, 2015.
  3. Lalande, L; Bourguignon, L; Bihari, S; Maire, P.; Neely, M; Jelliffe, R. and Goutelle, S Population Modeling and Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Isoniazid in Lungs. In Antimicrobial Agents and Chemotherapy, 59 (9): 5181-5189, 2015. doi 
  4. Rhodes, N. J; Gardiner, B. J; Neely, M. N; Grayson, M L.; Ellis, A. G; Lawrentschuk, N.; Frauman, A. G; Maxwell, K. M; Zembower, T. R and Scheetz, M. H Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. In Journal of Antimicrobial Chemotherapy, 70 (7): 2068-2073, 2015. doi 
  5. Jelliffe, R. W; Schumitzky, A.; Bayard, D.; Fu, X. and Neely, M. Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance. In Therapeutic drug monitoring, 37 (3): 389-394, 2015. doi 
  6. Neely, M.; Margol, A.; Fu, X.; Van Guilder, M.; Bayard, D.; Schumitzky, A.; Orbach, R.; Liu, S.; Louie, S. and Hope, W. Achieving target voriconazole concentrations more accurately in children and adolescents. In Antimicrobial Agents and Chemotherapy, 59 (6): 3090-3097, 2015. doi 
  7. Glatard, A.; Bourguignon, L.; Jelliffe, R. W; Maire, P.; Neely, M. N and Goutelle, S. Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients. In Antimicrobial Agents and Chemotherapy, 2015. doi 
  8. Neely, M.; Louie, S.; Xu, J.; Anthony, P.; Thuvamontolrat, K.; Mordwinkin, N. and Kovacs, A. Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy. doi  www 
  9. Rhodes, N. J; Kuti, J. L; Nicolau, D. P; Van Wart, S.; Nicasio, A. M; Liu, J.; Lee, B. J; Neely, M. N and Scheetz, M. H Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. In Antimicrobial Agents and Chemotherapy, 60 (3): 1401-1410, 2015. doi 

2014

  1. Frymoyer, A.; Hersh, A. L; El-Komy, M. H; Gaskari, S.; Su, F.; Drover, D. R and Van Meurs, K. Association between Vancomycin Trough Concentration and Area under the Concentration-Time Curve in Neonates. In Antimicrobial Agents and Chemotherapy, 58 (11): 6454-6461, 2014. doi 
  2. Louie, A.; Liu, W.; Vanguilder, M.; Neely, M. N; Schumitzky, A.; Jelliffe, R.; Fikes, S.; Kurhanewicz, S.; Robbins, N.; Brown, D.; Baluya, D. and Drusano, G. L Combination Treatment With Meropenem Plus Levofloxacin Is Synergistic Against Pseudomonas aeruginosa Infection in a Murine Model of Pneumonia. In Journal of Infectious Diseases, 211 (8): 1326-1333, 2014. doi 
  3. Yardley, M. M; Neely, M.; Huynh, N.; Asatryan, L.; Louie, S. G; Alkana, R. L and Davies, D. L Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. In Neuroreport, 25 (13): 1018-1023, 2014. doi 
  4. Neely, M.; Kaplan, E. L; Blumer, J. L; Faix, D. J and Broderick, M. P Serum Penicillin G Concentrations Are Below Inhibitory Concentrations by Two Weeks After Benzathine Penicillin G Injection in the Majority of Young Adults: A Population Pharmacokinetic Modeling Approach. In Antimicrobial Agents and Chemotherapy: AAC.02744-14, 2014. doi 
  5. Lodise, T. P; Drusano, G. L; Zasowski, E.; Dihmess, A.; Lazariu, V.; Cosler, L. and McNutt, L-A. Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?. In Clinical Infectious Diseases, 59 (5): 666-675, 2014. doi 
  6. Goutelle, S.; Bourguignon, L.; Maire, P.; Jelliffe, R. W and Neely, M. N The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy. In Current pharmaceutical design, 2014.
  7. Sheth, A N; Evans-Strickfaden, T; Haaland, R; Martin, A; Gatcliffe, C; Adesoye, A; Omondi, M W; Lupo, L D; Danavall, D; Easley, K; Chen, C Y; Pau, C P; Hart, C and Ofotokun, I HIV-1 Genital Shedding is Suppressed in the Setting of High Genital Antiretroviral Drug Concentrations Throughout the Menstrual Cycle. In Journal of Infectious Diseases, 210 (5): 736-744, 2014. doi 
  8. Le, J.; Ngu, B.; Bradley, J. S; Murray, W.; Nguyen, A.; Nguyen, L.; Romanowski, G. L; Vo, T. and Capparelli, E. V Vancomycin monitoring in children using bayesian estimation. doi  www 
  9. Bartroff, J.; Lai, T. L. and Narasimhan, B. A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies. In Statistics in Medicine, 33 (16): 2718-2735, 2014. doi 
  10. Felton, T W; Roberts, J A; Lodise, T P; Van Guilder, M.; Boselli, E; Neely, M N and Hope, W W Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy. In Antimicrobial Agents and Chemotherapy, 58 (7): 4094-4102, 2014. doi 
  11. Pai, M. P; Neely, M.; Rodvold, K. A and Lodise, T. P Innovative approaches to optimizing the delivery of vancomycin in individual patients. In Advanced Drug Delivery Reviews: 1-8, 2014. doi 
  12. Jelliffe, R. Concerning antiplatelet therapy. In The American journal of cardiology, 113 (12): 2086-2087, 2014. doi 
  13. Roberts, J. A; Abdul-Aziz, M. H; Lipman, J.; Mouton, J. W; Vinks, A. A; Felton, T. W; Hope, W. W; Farkas, A.; Neely, M. N; Schentag, J. J; Drusano, G.; Frey, O. R; Theuretzbacher, U.; Kuti, J. L; Pharmacology, on b. of T. I. S. of A-I.; Pharmacokinetics, t.; Microbiology, P. S. G. of t. E. S. of C. and Diseases, I. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. In The Lancet Infectious Diseases, 14 (6): 498-509, 2014. doi 
  14. Jelliffe, R. W; Milman, M.; Schumitzky, A.; Bayard, D. and Van Guilder, M. A two-compartment population pharmacokinetic-pharmacodynamic model of digoxin in adults, with implications for dosage. doi  www 
  15. Jelliffe, R. W The role of digitalis pharmacokinetics in converting atrial fibrillation and flutter to regular sinus rhythm. In Clinical Pharmacokinetics, 53 (5): 397-407, 2014. doi 
  16. Woillard, Jb; Lebreton, V; Neely, M; Turlure, P; Girault, S; Debord, J; Marquet, P and Saint-Marcoux, F Pharmacokinetic tools for the dose adjustment of cyclosporine in Hematopoietic Stem Cell transplant patients. In British Journal of Clinical Pharmacology: n/a-n/a, 2014. doi 
  17. Lunde, I.; Bremer, S.; Midtvedt, K.; Mohebi, B.; Dahl, M.; Bergan, S.; AAsberg, A. and Christensen, H. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. In European Journal of Clinical Pharmacology, 70 (6): 685-693, 2014. doi 
  18. Kinney, M E; Lamberski, N; Wack, R; Foster, R; Neely, M; Tell, L and Gehring, R Population pharmacokinetics of a single intramuscular administration of tulathromycin in adult desert tortoises (Gopherus agassizii). In Journal of veterinary pharmacology and therapeutics, 2014. doi 
  19. Owusu Obeng, A.; Egelund, E. F; Alsultan, A.; Peloquin, C. A and Johnson, J. A CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?. In Pharmacotherapy, 34 (7): 703-718, 2014. doi 
  20. AAsberg, A; Bjerre, A and Neely, M New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. In Pediatric transplantation, 18 (1): 103-111, 2014. doi 
  21. Neely, M. N; Youn, G.; Jones, B.; Jelliffe, R. W; Drusano, G. L; Rodvold, K. A and Lodise, T. P Are vancomycin trough concentrations adequate for optimal dosing?. In Antimicrobial Agents and Chemotherapy, 58 (1): 309-316, 2014. doi 
  22. Atrio, J.; Stanczyk, F. Z; Neely, M.; Cherala, G.; Kovacs, A. and Mishell, D. R Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women. In Journal of Acquired Immune Deficiency Syndromes, 65 (1): 72-77, 2014. doi 
  23. Drusano, G. L; Neely, M.; Van Guilder, M.; Schumitzky, A.; Brown, D.; Fikes, S.; Peloquin, C. and Louie, A. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. In PloS one, 9 (7): e101311-e101311, 2014. doi 
  24. Tatarinova, T.; Kryshchenko, A.; Triska, M.; Hassan, M.; Murphy, D.; Neely, M. and Schumitzky, A. NPEST: a nonparametric method and a database for transcription start site prediction. In Quantitative Biology, 2014. doi 
  25. Allegaert, K. and van den Anker, J. N Clinical pharmacology in neonates: small size, huge variability. In Neonatology, 105 (4): 344-349, 2014. doi 

2013

  1. Felton, T W; Goodwin, J; O'Connor, L; Sharp, A; Gregson, L; Livermore, J; Howard, S J; Neely, M N and Hope, W W Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. In Antimicrobial Agents and Chemotherapy, 57 (12): 5811-5819, 2013. doi 
  2. Loo, A. S; Neely, M.; Anderson, E. J; Ghossein, C.; McLaughlin, M. M and Scheetz, M. H Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis. In Antimicrobial Agents and Chemotherapy, 57 (12): 5854-5859, 2013. doi 
  3. AAsberg, A.; Midtvedt, K.; van Guilder, M.; Storset, E.; Bremer, S.; Bergan, S.; Jelliffe, R.; Hartmann, A. and Neely, M. N Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. In Transplant International, 26 (12): 1198-1207, 2013. doi 
  4. Narita, A.; Muramatsu, H.; Sakaguchi, H.; Doisaki, S.; Tanaka, M.; Hama, A.; Shimada, A.; Takahashi, Y.; Yoshida, N.; Matsumoto, K.; Kato, K.; Kudo, K.; Furukawa-Hibi, Y.; Yamada, K. and Kojima, S. Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children. In Journal of Pediatric Hematology/Oncology, 35 (5): e219-e223, 2013. doi 
  5. O'Connor, L.; Livermore, J.; Sharp, A. D; Goodwin, J.; Gregson, L.; Howard, S. J; Felton, T. W; Schwartz, J. A; Neely, M. N; Harrison, T. S; Perfect, J. R. and Hope, W. W Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. In Journal of Infectious Diseases, 208 (2): 351-361, 2013. doi 
  6. Hope, W. W; Vanguilder, M.; Donnelly, J. P.; Blijlevens, N. M A; Bruggemann, R. J M; Jelliffe, R. W and Neely, M. N Software for dosage individualization of voriconazole for immunocompromised patients. In Antimicrobial Agents and Chemotherapy, 57 (4): 1888-1894, 2013. doi 
  7. Tatarinova, T.; Neely, M.; Bartroff, J.; Van Guilder, M.; Yamada, W.; Bayard, D.; Jelliffe, R.; Leary, R.; Chubatiuk, A. and Schumitzky, A. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. In Journal of Pharmacokinetics and Pharmacodynamics, 40 (2): 189-199, 2013. doi 
  8. McCune, J. S; Baker, K S.; Blough, D. K; Gamis, A.; Bemer, M. J; Kelton-Rehkopf, M. C; Winter, L. and Barrett, J. S Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. In Journal of Clinical Pharmacology, 53 (3): 264-275, 2013. doi 
  9. Neely, M.; Rutstein, R.; Del Bianco, G.; Heresi, G.; Barton, T.; Wiznia, A.; Wiegand, R.; Wheeling, T.; Bohannon, B. and Dominguez, K. Use of Nucleoside Reverse Transcriptase Inhibitor Only Regimens in HIV-infected Children and Adolescents. In Pediatric Infectious Disease Journal: 1, 2013. doi 
  10. Sedghizadeh, P. P; Jones, A. C; LaVallee, C.; Jelliffe, R. W; Le, A. D; Lee, P.; Kiss, A. and Neely, M. Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw. In Oral surgery, oral medicine, oral pathology and oral radiology, 115 (2): 224-232, 2013. doi 
  11. Choi, S-H.; Lee, S-Y.; Hwang, J-Y.; Lee, S. H.; Yoo, K. H.; Sung, Ki W.; Koo, H. H. and Kim, Y-J. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. In Pediatric Blood & Cancer, 60 (1): 82-87, 2013. doi 
  12. Matar, K. M; Al-lanqawi, Y.; Abdul-Malek, K. and Jelliffe, R. Amikacin population pharmacokinetics in critically ill Kuwaiti patients. In BioMed research international, 2013: 202818, 2013. doi 
  13. Neely, M N and Rakhmanina, N Y Pharmacokinetic targets of antiretroviral therapy in children and adolescents. In Journal of Pediatric and Neonatal Individualized Medicine, 2 (2): e020226, 2013. doi 

2012

  1. Zhao, W.; Piana, C.; Danhof, M.; Burger, D.; Della Pasqua, O. and Jacqz-Aigrain, E. Population pharmacokinetics of abacavir in infants, toddlers and children. In British Journal of Clinical Pharmacology: -, 2012. doi 
  2. Schaudinn, C.; Gorur, A.; Webster, P.; Jones, A. C; Neely, M.; Jelliffe, R. W; Le, A. D and Sedghizadeh, P. P Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosis. In Oral surgery, oral medicine, oral pathology and oral radiology, 114 (4): 480-486, 2012. doi 
  3. Krekels, E H J; Neely, M; Panoilia, E; Tibboel, D; Capparelli, E; Danhof, M; Mirochnick, M and Knibbe, C A J From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part ItextendashExtrapolation of a Covariate Model From Morphine to Zidovudine. In CPT: Pharmacometrics & Systems Pharmacology, 1 (10): e9-, 2012. doi 
  4. Montoya, J. G JG; Neely, M. N MN; Gupta, S. S; Lunn, M. R MR; Loomis, K. S KS; Pritchett, J. C JC; Polsky, B. B and Medveczky, P. G PG Antiviral therapy of two patients with chromosomally-integrated human herpesvirus-6A presenting with cognitive dysfunction. In Journal of Clinical Virology, 55 (1): 40-45, 2012. doi 
  5. Neely, M. N; van Guilder, M. G; Yamada, W. M; Schumitzky, A. and Jelliffe, R. W Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. In Therapeutic drug monitoring, 34 (4): 467-476, 2012. doi 
  6. Felton, T W; Hope, W W; Lomaestro, B M; Butterfield, J M; Kwa, A L; Drusano, G.L. and Lodise, T P Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. In Antimicrobial Agents and Chemotherapy, 56 (8): 4087-4094, 2012. doi 
  7. Pascual, A.; Csajka, C.; Buclin, T.; Bolay, S.; Bille, J.; Calandra, T. and Marchetti, O. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. In Clinical Infectious Diseases, 55 (3): 381-390, 2012. doi 
  8. Jelliffe, R. W Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy. doi  www 
  9. Dolton, M. J; Ray, J. E; Chen, S. C-A.; Ng, K.; Pont, L. G and McLachlan, A. J Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring: A Multi-Center Study. In Antimicrobial Agents and Chemotherapy, 56 (9): 4793-4799, 2012. doi 
  10. Arab-Alameddine, M.; Fayet-Mello, A.; Lubomirov, R.; Neely, M.; di Iulio, J.; Owen, A.; Boffito, M.; Cavassini, M.; G"unthard, H. F; Rentsch, K.; Buclin, T.; Aouri, M.; Telenti, A.; Decosterd, L. A.; Rotger, M.; Csajka, C. and Group, S. H. C. S. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. In Antimicrobial Agents and Chemotherapy, 56 (6): 2959-2966, 2012. doi 
  11. Rakhmanina, N. Y; Neely, M. N and Capparelli, E. V High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count. doi  www 
  12. Homans, J.; Christensen, S.; Stiller, T.; Wang, C-H.; Mack, W.; Anastos, K.; Minkoff, H.; Young, M.; Greenblatt, R.; Cohen, M.; Strickler, H.; Karim, R.; Spencer, L. Y.; Operskalski, E.; Frederick, T. and Kovacs, A. Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. In Journal of Acquired Immune Deficiency Syndromes, 60 (1): 99-110, 2012. doi 
  13. Kelly, L E; Rieder, M; van den Anker, J; Malkin, B; Ross, C; Neely, M N; Carleton, B; Hayden, M R; Madadi, P and Koren, G More Codeine Fatalities After Tonsillectomy in North American Children. In Pediatrics, 129 (5): e1343-e1347, 2012. doi 
  14. Zhao, W. W; Cella, M. M; Della Pasqua, O. O; Burger, D. D and Jacqz-Aigrain, E. E Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. In British Journal of Clinical Pharmacology, 73 (4): 641-650, 2012. doi 
  15. Charhon, N.; Neely, M. N; Bourguignon, L.; Maire, P.; Jelliffe, R. W and Goutelle, S. Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients. In Antimicrobial Agents and Chemotherapy, 56 (4): 1862-1869, 2012. doi 
  16. Doby, E. H; Benjamin, D. K; Blaschke, A. J; Ward, R. M; Pavia, A. T; Martin, P. L; Driscoll, T. A; Cohen-Wolkowiez, M. and Moran, C. Therapeutic Monitoring of Voriconazole in Children Less Than 3 Years of Age: A Case Report and Summary of Voriconazole Concentrations for 10 Children. In Pediatric Infectious Disease Journal, 2012. doi 
  17. Hope, W. W Population pharmacokinetics of voriconazole in adults. In Antimicrobial Agents and Chemotherapy, 56 (1): 526-531, 2012. doi 
  18. Siberry, G. K; Frederick, T.; Emmanuel, P.; Paul, M. E; Bohannon, B.; Wheeling, T.; Barton, T.; Rathore, M. H and Dominguez, K. L Methicillin-Resistant Staphylococcus aureus Infections in Human Immunodeficiency Virus-Infected Children and Adolescents. In AIDS research and treatment, 2012: 627974, 2012. doi 

2011

  1. Neely, M. and Louie, S. Obesity and its impact on drug therapy: are we ready for this change?. In Clinical Pharmacokinetics, 50 (12): 825-826, 2011. doi 
  2. Schein, R; Homans, J; Larsen, R A and Neely, M Posaconazole for Chronic Refractory Coccidioidal Meningitis. In Clinical Infectious Diseases, 53 (12): 1252-1254, 2011. doi 
  3. Troke, P.F.; Hockey, H P and Hope, W W Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. In Antimicrobial Agents and Chemotherapy, 55 (10): 4782-4788, 2011. doi 
  4. Bondareva, I.B.; Jelliffe, R W; Andreeva, O V and Bondareva, K I Predictability of individualized dosage regimens of carbamazepine and valproate. In Journal of clinical pharmacy and therapeutics, 36 (5): 625-636, 2011. doi 
  5. Jelliffe, R.; Neely, M.; Schumitzky, A.; Bayard, D.; Van Guilder, M.; Botnen, A.; Bustad, A.; Laing, D.; Yamada, W.; Bartroff, J. and Tatarinova, T. Nonparametric population modeling and Bayesian analysis. In Pharmacol Res., 64 (4): 426, 2011. doi 
  6. Goutelle, S.; Bourguignon, L.; Jelliffe, R. W; Conte, J. E Jr and Maire, P. Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin. In J Theor.Biol., 282 (1): 80-92, 2011. doi 
  7. Rakhmanina, N. Y; Neely, M. N; van Schaik, R. H N; Gordish-Dressman, H. A; Williams, K. D; Soldin, S. J and van den Anker, J. N CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. doi  www 
  8. Bartroff, J. and Lai, T. L. Incorporating individual and collective ethics into phase I cancer trial designs. In Biometrics, 67 (2): 596-603, 2011. doi 
  9. Garvie, P. A; Flynn, P. M; Belzer, M.; Britto, P.; Hu, C.; Graham, B.; Neely, M.; McSherry, G. D; Spector, S. A; Gaur, A. H and Team, P. A. C. T. G. (. P. Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study. In The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 48 (6): 637-640, 2011. doi 
  10. Neely, M. N and Rakhmanina, N. Y Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. In Clinical Pharmacokinetics, 50 (3): 143-189, 2011. doi 
  11. Spriet, I; Cosaert, K; Renard, M; Uyttebroeck, A; Meyts, I; Proesmans, M; Meyfroidt, G; de Hoon, J; Verbesselt, R and Willems, L Voriconazole plasma levels in children are highly variable. In Eur J Clin Microbiol Infect Dis, 30 (2): 283-287, 2011. doi 
  12. Hassan, A.; Burhenne, J.; Riedel, K-D.; Weiss, J.; Mikus, G.; Haefeli, W. E and Czock, D. Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring. doi  www 
  13. Darbari, D. S; Neely, M.; van den Anker, J. and Rana, S. Increased Clearance of Morphine in Sickle Cell Disease: Implications for Pain Management. In The Journal of Pain, 2011. doi 
  14. McIlleron, H.; Ren, Y.; Nuttall, J.; Fairlie, L.; Rabie, H.; Cotton, M.; Eley, B.; Meyers, T.; Smith, P. J; Merry, C. and Maartens, G. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. In Antiviral Therapy, 16 (3): 417-421, 2011. doi 
  15. Else, L. J; Taylor, S.; Back, D. J and Khoo, S. H Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. In Antiviral Therapy, 16 (8): 1149-1167, 2011. doi 
  16. Launay, O.; Tod, M.; Tsch"ope, I.; Si-Mohamed, A.; Belarbi, L.; Charpentier, C.; Goujard, C.; Taburet, A-M.; Lortholary, O.; Leroy, V.; Belec, L. and Group, t. A. E. G. S. Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. In Antiviral Therapy, 16 (6): 843-852, 2011. doi 
  17. Watt, K.; Benjamin Jr, D. K. and Cohen-Wolkowiez, M. Pharmacokinetics of antifungal agents in children. In Early Human Development, 87: S61-S65, 2011. doi 
  18. Darbari, D S; Neely, M; van den Anker, J and Rana, S Increased clearance of morphine in sickle cell disease: implications for pain management. In The Journal of Pain, 2011.

2010

  1. Henning, T. R.; Kissinger, P.; Lacour, N.; Meyaski-Schluter, M.; Clark, R. and Amedee, A. M. Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women. In Journal of Infectious Diseases, 202 (10): 1543-1552, 2010. doi 
  2. Neely, M.; Decosterd, L.; Fayet, A.; Lee, J. S. F.; Margol, A.; Kanani, M.; di Iulio, J.; von Schoen-Angerer, T.; Jelliffe, R. and Calmy, A. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. In Antimicrobial Agents and Chemotherapy, 54 (11): 4619-4625, 2010. doi 
  3. Walsh, T.J.; Driscoll, T; Milligan, P A; Wood, N.D.; Schlamm, H.; Groll, A.H.; Jafri, H; Arrieta, A C; Klein, N J and Lutsar, I. Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. In Antimicrobial Agents and Chemotherapy, 54 (10): 4116-4123, 2010. doi 
  4. Gaur, A. H; Belzer, M.; Britto, P.; Garvie, P. A; Hu, C.; Graham, B.; Neely, M.; McSherry, G.; Spector, S. A; Flynn, P. M and Team, P. A. C. T. G. P. Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. In AIDS Research and Human Retroviruses, 26 (9): 947-953, 2010. doi 
  5. Walsh, T. J; Goutelle, S.; Jelliffe, R. W; Golden, J. A; Little, E. A; DeVoe, C.; Mickiene, D.; Hayes, M. and Conte, J. E Jr Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients. In Antimicrobial Agents and Chemotherapy, 54 (8): 3451-3459, 2010. doi 
  6. Michael, C.; Bierbach, U.; Frenzel, K.; Lange, T.; Basara, N.; Niederwieser, D.; Mauz-Korholz, C. and Preiss, R. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. In Antimicrobial Agents and Chemotherapy, 54 (8): 3225-3232, 2010. doi 
  7. Neely, M. and Jelliffe, R. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. In Journal of Clinical Pharmacology, 50 (7): 842-847, 2010. doi 
  8. Rakhmanina, N. Y; van den Anker, J. N; Soldin, S. J; van Schaik, R. H; Mordwinkin, N. and Neely, M. N Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?. In Therapeutic drug monitoring, 32 (3): 273-281, 2010. doi 
  9. Neely, M. N and Rakhmanina, N. Y Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. In Journal of Antimicrobial Chemotherapy, 65 (4): 808-9; author reply 809-10, 2010. doi 
  10. Drusano, G.L. How Many Steps along the Path Is Too Far?. In Clinical Infectious Diseases, 50 (1): 37-39, 2010. doi 
  11. Neely, M.; Rushing, T.; Kovacs, A.; Jelliffe, R. and Hoffman, J. Voriconazole Pharmacokinetics and Pharmacodynamics in Children. In Clinical Infectious Diseases, 50 (1): 27-36, 2010. doi 
  12. Walsh, T. J; Driscoll, T.; Milligan, P. A; Wood, N. D.; Schlamm, H.; Groll, A. H.; Jafri, H.; Arrieta, A. C.; Klein, N. J. and Lutsar, I. Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. In Antimicrobial Agents and Chemotherapy, 54 (10): 4116-4123, 2010. doi 
  13. Michael, C.; Bierbach, U.; Frenzel, K.; Lange, T.; Basara, N.; Niederwieser, D.; Mauz-Korholz, C. and Preiss, R. Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients. In Antimicrobial Agents and Chemotherapy, 54 (8): 3225-3232, 2010. doi 
  14. Elsherbiny, D.; Ren, Y.; McIlleron, H.; Maartens, G. and Simonsson, U. S H Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. In European Journal of Clinical Pharmacology, 2010. doi 
  15. Bartroff, J. and Lai, T. L Approximate dynamic programming and its applications to the design of phase I cancer trials. In Statistical Science, 25 (2): 245-257, 2010.
  16. Miyakis, S.; van Hal, S. J; Solvag, C. J. S; Ray, J. and Marriott, D. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory. doi  www 

2009

  1. Goutelle, S.; Bourguignon, L.; Bertrand-Passeron, N.; Jelliffe, R. W and Maire, P. Visual estimation of patients' body weight in hospital: the more observers, the better?. In Pharmacy world & science : PWS, 31 (4): 422-425, 2009. doi 
  2. Goutelle, S.; Bourguignon, L.; Maire, P. H; Van Guilder, M.; Conte, J. E and Jelliffe, R. W Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. In Antimicrobial Agents and Chemotherapy, 53 (7): 2974-2981, 2009. doi 
  3. Rakhmanina, N.; van den Anker, J.; Baghdassarian, A.; Soldin, S.; Williams, K. and Neely, M. N Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. In Antimicrobial Agents and Chemotherapy, 53 (6): 2532-2538, 2009. doi 
  4. Neely, M. and Kovacs, A. Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. In Therapeutics and clinical risk management, 5 (3): 595-615, 2009.
  5. Sleasman, J W; Robbins, B L; Cross, S J; Lindsey, J C; Kraimer, J M; Heckman, B E; Sprenger, H L; Tustin, N B; Rose, C H; Poston, P A; Neal, E F; Pakes, G E; Nikanjam, M and Capparelli, E V Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. In Clinical Pharmacology and Therapeutics, 85 (4): 394-401, 2009. doi 
  6. Troukhan, M.; Tatarinova, T.; Bouck, J.; Flavell, R. B and Alexandrov, N. N Genome-wide discovery of cis-elements in promoter sequences using gene expression. In Omics : a journal of integrative biology, 13 (2): 139-151, 2009. doi 
  7. Jelliffe, R.; Schumitzky, A.; Bayard, D.; Leary, R.; Botnen, A.; Guilder, M. V.; Bustad, A. and Neely, M Human Genetic Variation, Population Pharmacokinetic-Dynamic Models, Bayesian Feedback Control, and Maximally Precise Individualized Drug Dosage Regimens. In Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacog, 7 (4): 249-262, 2009.

2008

  1. Jelliffe, R. Estimation of creatinine clearance. doi  www 
  2. Neely, M. and Jelliffe, R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. doi  www 
  3. Tatarinova, T.; Bouck, J. and Schumitzky, A. Kullback-Leibler Markov chain Monte Carlo--a new algorithm for finite mixture analysis and its application to gene expression data. In Journal of bioinformatics and computational biology, 6 (4): 727-746, 2008.
  4. Kwa, A.; Sprung, J.; Guilder, M. V. and Jelliffe, R. W A population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine. www 
  5. Macdonald, I.; Staatz, C. E; Jelliffe, R. W and Thomson, A. H Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. In Therapeutic drug monitoring, 30 (1): 67-74, 2008. doi 
  6. Kiser, J J; Carten, M L; Aquilante, C L; Anderson, P.L.; Wolfe, P; King, T M; Delahunty, T; Bushman, L R and Fletcher, C V The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. In Clinical Pharmacology and Therapeutics, 83 (2): 265-272, 2008. doi 

2007

  1. Greenhalgh, D. G; Saffle, J. R; Holmes IV, J. H; Gamelli, R. L; Palmieri, T. L; Horton, J. W; Tompkins, R. G; Traber, D. L; Mozingo, D. W; Deitch, E. A; Goodwin, C. W; Herndon, D. N; Gallagher, J. J; Sanford, A. P; Jeng, J. C; Ahrenholz, D. H; Neely, A. N; O'Mara, M. S; Wolf, S. E; Purdue, G. F; Garner, W. L; Yowler, C. J and Latenser, B. A American Burn Association Consensus Conference to Define Sepsis and Infection in Burns. In Journal of Burn Care & Research, 28 (6): 776-790, 2007. doi 
  2. Neely, M. N; Benning, L.; Xu, J.; Strickler, H. D; Greenblatt, R. M; Minkoff, H.; Young, M.; Bremer, J.; Levine, A. M and Kovacs, A. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. In Journal of Acquired Immune Deficiency Syndromes, 44 (1): 38-42, 2007. doi 

2006

  1. Shoemaker, W. C; Wo, C. C J; Lu, K.; Chien, L-C.; Rhee, P.; Bayard, D.; Demetriades, D. and Jelliffe, R. W Noninvasive hemodynamic monitoring for combat casualties. In Military medicine, 171 (9): 813-820, 2006.
  2. Shoemaker, W. C; Bayard, D. S.; Wo, C. C J; Botnen, A.; Chan, L. S; Chien, L-C.; Lu, K.; Demetriades, D.; Belzberg, H. and Jelliffe, R. W Stochastic model for outcome prediction in acute illness. In Computers in Biology and Medicine, 36 (6): 585-600, 2006. doi 
  3. Bondareva, I.B.; Jelliffe, R W; Gusev, E I; Guekht, A B; Melikyan, E G and Belousov, Y B Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. In Journal of clinical pharmacy and therapeutics, 31 (3): 211-221, 2006. doi 
  4. Benjamin, D K; Driscoll, T; Seibel, N L; Gonzalez, C E; Roden, M M; Kilaru, R; Clark, K; Dowell, J A; Schranz, J and Walsh, T.J. Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections. In Antimicrobial Agents and Chemotherapy, 50 (2): 632-638, 2006. doi 
  5. Shoemaker, W. C; Wo, C. C J; Lu, K.; Chien, L-C.; Bayard, D. S.; Belzberg, H.; Demetriades, D. and Jelliffe, R. W Outcome prediction by a mathematical model based on noninvasive hemodynamic monitoring. In J Trauma, 60 (1): 82-90, 2006. doi 
  6. Bustad, A.; Terziivanov, D.; Leary, R.; Port, R.; Schumitzky, A. and Jelliffe, R. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. In Clinical Pharmacokinetics, 45 (4): 365-383, 2006.

2005

  1. Adamson, P.; Walsh, T. J; Seibel, N. L; Flynn, P. M; Neely, M. N; Schwartz, C.; Shad, A.; Kaplan, S. L; Roden, M. M; Stone, J. A; Miller, A.; Bradshaw, S. K; Li, S. X; Sable, C. A and Kartsonis, N. A Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. In Antimicrobial Agents and Chemotherapy, 49 (11): 4536-4545, 2005. doi 
  2. Shoemaker, W. C; Bayard, D. S.; Wo, C. C J; Chan, L. S; Chien, L-C.; Lu, K. and Jelliffe, R. W Outcome prediction in chest injury by a mathematical search and display program. In Chest, 128 (4): 2739-2748, 2005. doi 
  3. Shoemaker, W. C; Bayard, D. S.; Botnen, A.; Wo, C. C J; Gandhi, A.; Chien, L-C.; Lu, K.; Martin, M. J; Chan, L. S; Demetriades, D.; Ahmadpour, N. and Jelliffe, R. W Mathematical program for outcome prediction and therapeutic support for trauma beginning within 1 hr of admission: a preliminary report. In Critical care medicine, 33 (7): 1499-1506, 2005.
  4. Shoemaker, W. C; Bayard, D. S.; Wo, C. C J; Botnen, A.; Ahmedpour, N.; Gandhi, A.; Demetriades, D. and Jelliffe, R. W A stochastic control program to predict outcome and to support therapeutic decisions: a preliminary report. In Journal of clinical monitoring and computing, 19 (3): 223-230, 2005. doi 

2004

  1. Gan, S H; Ismail, R; Wan Adnan, W A; Zulmi, W and Jelliffe, R W Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. In Journal of clinical pharmacy and therapeutics, 29 (5): 455-463, 2004. doi 
  2. Neely, M. and Kovacs, A. Management of antiretroviral therapy in neonates, children, and adolescents. In Current HIV/AIDS reports, 1 (2): 97-104, 2004.
  3. Bondareva, I.B.; Jelliffe, R W; Sokolov, A.V. and Tischenkova, I.F. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. In Journal of clinical pharmacy and therapeutics, 29 (2): 105-120, 2004.
  4. Jelliffe, R. Individual dose optimization: why and how. In International Journal of Clinical Pharmacology and Therapeutics, 42 (3): 183-184, 2004.
  5. Port, R. E; Kiepe, D.; Van Guilder, M.; Jelliffe, R. W and Mehls, O. Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage. In Clinical Pharmacokinetics, 43 (1): 57-70, 2004. doi 
  6. Bayard, D. S. and Jelliffe, R. W A Bayesian approach to tracking patients having changing pharmacokinetic parameters. In Journal of Pharmacokinetics and Pharmacodynamics, 31 (1): 75-107, 2004. doi 

2003

  1. Neely, M. and Kovacs, A. Management of Antiretroviral Therapy in Neonates, Children, and Adolescents. In Current infectious disease reports, 5 (6): 521-530, 2003.
  2. Martin, P; Bleyzac, N.; Souillet, G; Galambrun, C; Bertrand, Y; Maire, P.H.; Jelliffe, R W and Aulagner, G. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. In Bone Marrow Transplantation, 32 (9): 881-887, 2003.
  3. Neely, M.; Kalyesubula, I.; Bagenda, D.; Myers, C. and Olness, K. Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. In African Health Sciences, 3 (2): 61-67, 2003.
  4. Rougier, F; Corvaisier, S.; Ducher, M.; Claude, D; Jelliffe, R W and Maire, P. [PK/PD modeling of aminoglycoside nephrotoxicity]. In Pathol.Biol.(Paris), 51 (4): 234-236, 2003.
  5. Rougier, F.; Claude, D.; Maurin, M.; Sedoglavic, A.; Ducher, M.; Corvaisier, S.; Jelliffe, R. and Maire, P. Aminoglycoside nephrotoxicity: modeling, simulation, and control. In Antimicrobial Agents and Chemotherapy, 47 (3): 1010-1016, 2003.
  6. Jelliffe, R. Proposed 'observation post'. In Australian family physician, 32 (3): 103-106, 2003.
  7. Vinks, A. A; Den Hollander, J. G; Overbeek, S. E; Jelliffe, R. W and Mouton, J. W Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. In Antimicrobial Agents and Chemotherapy, 47 (2): 541-547, 2003.
  8. Rougier, F.; Ducher, M.; Maurin, M.; Corvaisier, S.; Claude, D.; Jelliffe, R. and Maire, P. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. In Clinical Pharmacokinetics, 42 (5): 493-500, 2003. doi 
  9. A, B.; C, P. and Jelliffe, R. Gentamicin Ototoxicity: Characteristics of Patient Response Analyzed with Saturable Michaelis-Menten Models. In Presented at the 4th International Meeting on Mathematical Modeling, Technical University of Vienna, Vienna, Austria, 2003.

2002

  1. Bayard, D. Proof of quasi-adaptivity for the m-measurement feedback class of stochastic control policies. In Automatic Control, IEEE Transactions, 32 (5): 447-451, 2002.
  2. Aminimanizani, A.; Beringer, P.M.; Kang, J.; Tsang, L.; Jelliffe, R W and Shapiro, B.J. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. In Journal of Antimicrobial Chemotherapy, 50 (4): 553-559, 2002.
  3. Nelson, P. W and Perelson, A. S Mathematical analysis of delay differential equation models of HIV-1 infection. In Mathematical Biosciences, 179 (1): 73-94, 2002.

2001

  1. Montgomery, M J; Beringer, P.M.; Aminimanizani, A.; Louie, S G; Shapiro, B.J.; Jelliffe, R. and Gill, M.A. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. In Antimicrobial Agents and Chemotherapy, 45 (12): 3468-3473, 2001. doi 
  2. Bondareva, I.B.; Sokolov, A.V.; Tischenkova, I.F. and Jelliffe, R W Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage. In Journal of clinical pharmacy and therapeutics, 26 (3): 213-223, 2001.
  3. Milman, M.; Jiang, F. and Jelliffe, R. Creating discrete joint densities from continuous ones: the moment matching-maximum entropy approach. In Computers in Biology and Medicine, 31 (3): 197-214, 2001.
  4. Labaune, J.M.; Bleyzac, N.; Maire, P.; Jelliffe, R W; Boutroy, M.J.; Aulagner, G. and Putet, G. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. In Biol.Neonate, 80 (2): 142-147, 2001.
  5. Bleyzac, N.; Souillet, G; Magron, P.; Janoly, A.; Martin, P; Bertrand, Y; Galambrun, C; Dai, Q.; Maire, P.; Jelliffe, R W and Aulagner, G. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. In Bone Marrow Transplantation, 28 (8): 743-751, 2001.
  6. Aminimanizani, A.; Beringer, P and Jelliffe, R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. In Clinical Pharmacokinetics, 40 (3): 169-187, 2001. doi 
  7. Ducher, M.; Maire, P.; Cerutti, C.; Bourhis, Y; Foltz, F; Sorensen, P; Jelliffe, R. and Fauvel, J.P. Renal elimination of amikacin and the aging process. In Clinical Pharmacokinetics, 40 (12): 947-953, 2001. doi 
  8. Jelliffe, R W and Maire, P. Goal-oriented, model-based drug regimens. In Comput.Biol.Med., 31 (3): 145-146, 2001.
  9. Breilh, D.; Saux, M.C.; Maire, P.; Vergnaud, J.M. and Jelliffe, R W Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. In Comput.Biol.Med., 31 (3): 147-155, 2001.
  10. Bleyzac, N.; Varnier, V.; Labaune, J.M.; Corvaisier, S.; Maire, P.; Jelliffe, R W; Putet, G. and Aulagner, G. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. In Eur.J.Clin.Pharmacol., 57 (6-7): 499-504, 2001.
  11. Zhu, M; Burman, W J; Jaresko, G S; Berning, S E; Jelliffe, R W and Peloquin, C A Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. In Pharmacotherapy, 21 (9): 1037-1045, 2001.
  12. Leary, R.H.; Jelliffe, R.; Schumitzky, A. and Van Guilder, M. An adaptive grid non-parametric approach to population pharmacokinetic/dynamic (PK/PD) population models. In Proceedings, 14th IEEE symposium on Computer Based Medical Systems, 1 (1): 389-394, 2001.
  13. Macchi-Andanson, M.; Charpiat, B.; Jelliffe, R W; Ducerf, C.; Fourcade, N. and Baulieux, J. Failure of traditional trough levels to predict tacrolimus concentrations. www 

2000

  1. Jelliffe, R.; Bayard, D.; Milman, M.; Van Guilder, M. and Schumitzky, A. Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens. In Therapeutic drug monitoring, 22 (3): 346-353, 2000.
  2. Bleyzac, N.; Allard-Latour, B; Laffont, A.; Mouret, J; Jelliffe, R. and Maire, P. Diurnal changes in the pharmacokinetic behavior of amikacin. www 
  3. Jelliffe, R. Goal-oriented, model-based drug regimens: setting individualized goals for each patient. www 
  4. Jelliffe, R.; Schumitzky, A. and Van Guilder, M. Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods. www 
  5. Beringer, P.M.; Vinks, A.A.; Jelliffe, R W and Shapiro, B.J. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. In Antimicrobial Agents and Chemotherapy, 44 (4): 809-813, 2000.
  6. Leary, R.H. Global Optimization on Funneling Landscapes. In Journal of Global Optimization, 18: 367-383, 2000.

1999

  1. Peloquin, C A; Bulpitt, A E; Jaresko, G S; Jelliffe, R W; Childs, J.M. and Nix, D E Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. In Antimicrobial Agents and Chemotherapy, 43 (3): 568-572, 1999.
  2. Leary, R.H. and Doye, J.P.K. Tetrahedral global minimum for the 98-atom Lennard-Jones cluster. In Physical Review E, 60: R6320-R6322, 1999.

1998

  1. Corvaisier, S.; Maire, P.H.; Bouvier d'Yvoire, M.Y.; Barbaut, X.; Bleyzac, N. and Jelliffe, R W Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. In Antimicrobial Agents and Chemotherapy, 42 (7): 1731-1737, 1998.
  2. Charpiat, B.; Falconi, I.; Breant, V.; Jelliffe, R W; Sab, J.M.; Ducerf, C.; Fourcade, N.; Thomasson, A. and Baulieux, J. A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. www 
  3. Shafran, S.D.; Singer, J.; Zarowny, D.P.; Deschenes, J.; Phillips, P.; Turgeon, F.; Aoki, F.Y.; Toma, E.; Miller, M.; Duperval, R.; Lemieux, C. and Schlech, W.F. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. In Journal of Infectious Diseases, 177 (1): 252-255, 1998.
  4. Jelliffe, R W; Schumitzky, A.; Bayard, D.; Milman, M.; Van Guilder, M.; Wang, X.; Jiang, F.; Barbaut, X. and Maire, P. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals. In Clinical Pharmacokinetics, 34 (1): 57-77, 1998.
  5. Beringer, P.M.; Vinks, A.A. and Jelliffe, R W Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. In Journal of Antimicrobial Chemotherapy, 41 (1): 142-144, 1998.
  6. Peloquin, C A; Bulpitt, A E; Jaresko, G S; Jelliffe, R W; James, G.T. and Nix, D E Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. In Pharmacotherapy, 18 (6): 1205-1211, 1998.

1997

  1. Peloquin, C A; Jaresko, G S; Yong, C L; Keung, A C; Bulpitt, A E and Jelliffe, R W Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. In Antimicrobial Agents and Chemotherapy, 41 (12): 2670-2679, 1997.
  2. Jelliffe, R W; Gomis, P.; Tahani, B.; Ruskin, J. and Sattler, F.R. A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods. www 

1996

  1. Vincent, S.; Maire, P.H.; Bataillard, T.; Denjean, E.; Ducrozet, P.; Laffont, A.; Visent, C. and Jelliffe, R W [Individual variability of pharmacokinetic parameters of amikacin in the elderly: retrospective studies]. In Pathol.Biol.(Paris), 44 (7): 667-674, 1996.
  2. Breant, V.; Charpiat, B.; Sab, J.M.; Maire, P. and Jelliffe, R W How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to cyclosporine. In European Journal of Clinical Pharmacology, 51 (3-4): 283-288, 1996.

1995

  1. Maire, P.H.; Barbaut, X.; Thalabard, J.C.; Vergnaud, J.M.; Roux, D.; Roy, M. and Jelliffe, R W Adaptive control of therapeutic drug regimens relations between clinical situations: outcomes and simulations using nonlinear dynamic models. In Medinfo., 8 Pt 2: 1111-1115, 1995.
  2. Jelliffe, R W; Bayard, D.; Schumitzky, A.; Milman, M. and Van Guilder, M. Pharmaco-informatics: more precise drug therapy from 'multiple model' (MM) adaptive control regimens: evaluation with simulated vancomycin therapy. In Medinfo., 8 Pt 2: 1106-1110, 1995.

1994

  1. Dodge, W.F.; Jelliffe, R W; Zwischenberger, J.B.; Bellanger, R.A.; Hokanson, J.A. and Snodgrass, W.R. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. www 
  2. Jelliffe, R W; Maire, P.; Sattler, F.; Gomis, P. and Tahani, B. Adaptive control of drug dosage regimens: basic foundations, relevant issues, and clinical examples. In International Journal of Bio-Medical Computing, 36 (1-2): 1-23, 1994.
  3. Neef, C.; Jelliffe, R W; van Laar, T.; Loohuis, T.; Essink, A.W. and Janssen, E.N. Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. In International Journal of Bio-Medical Computing, 36 (1-2): 143-150, 1994.
  4. Maire, P.; Barbaut, X.; Vergnaud, J.M.; el Brouzi, M.; Confesson, M.A.; Pivot, C.; Chuzeville, M.; Ivanoff, N.; Brazier, J.L. and Jelliffe, R W Computation of drug concentrations in endocardial vegetations in patients during antibiotic therapy. In International Journal of Bio-Medical Computing, 36 (1-2): 77-85, 1994.
  5. Maire, P.; Barbaut, X.; Girard, P.; Mallet, A.; Jelliffe, R W and Berod, T. Preliminary results of three methods for population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients. In International Journal of Bio-Medical Computing, 36 (1-2): 139-141, 1994.
  6. Grillot, M.; Maire, P.H.; Confesson, M.A.; Cogoluenhes, V.; Pivot, C.; Druguet, M.; Courpron, P. and Jelliffe, R W [Adaptive control of therapeutics using amikacin in very old patients: retrospective analysis of efficacy and toxicity]. In Pathol.Biol.(Paris), 42 (3): 247-253, 1994.
  7. Confesson, M.A.; Barbaut, X.; Maire, P.; Vergnaud, J.M.; el Brouzi, A. and Jelliffe, R W [Aminoglycoside determinations calculated in endocarditis vegetations. Relations with clinical practices during infectious endocarditis treatment with amikacin]. In Therapie, 49 (1): 27-34, 1994.
  8. Bayard, D.S.; Milman, M. H. and Schumitzky, A. Design of dosage regimens: A multiple model stochastic control approach. In International Journal of Bio-Medical Computing, 36 (1-2): 103-115, 1994.
  9. Jelliffe, R W; Bayard, D.; Schumitzky, A.; Milman, M. and Van Guilder, M. Pharmaco-informatics: more precise drug therapy from "multiple model" (MM) stochastic adaptive control regimens: evaluation with simulated vancomycin therapy. In Proceedings of the Annual Symposium of Computer Applications in Medical Care: 972, 1994.
  10. Jelliffe, R W; Bayard, D.; Schumitzky, A.; Milman, M. and Van Guilder, M. Pharmacoinformatics: more precise drug therapy from "multiple model" (MM) stochastic adaptive control regimens: evaluation with simulated vancomycin therapy. In Proceedings of the Annual Symposium of Computer Applications in Medical Care: 972, 1994.
  11. Charpiat, B.; Breant, V.; Pivot-Dumarest, C.; Maire, P. and Jelliffe, R. Prediction of future serum concentrations with Bayesian fitted pharmacokinetic models: results with data collected by nurses versus trained pharmacy residents. www 

1993

  1. Sittig, D.F.; Jiang, Z. and Jelliffe, R W A graphical user interface to facilitate patient-specific drug dosing. In Journal of Medical Systems, 17 (5): 327-333, 1993.
  2. Jelliffe, R W and Tahani, B. Pharmacoinformatics: equations for serum drug assay error patterns; implications for therapeutic drug monitoring and dosage. In Proceedings of the Annual Symposium of Computer Applications in Medical Care: 517-521, 1993.
  3. Schumitzky, A. The nonparametric maximum likelihood approach to pharmacokinetic population analysis. In Proceedings of the Western Simulation Multiconference, Simulation in Healthcare: 95-100, 1993.
  4. Spieler, G. and Schumitzky, A. Asymptotic analysis of extended least squares estimators with application to population pharmacokinetics. In Proceedings: Biopharmaceutical Section: 177-182, 1993.
  5. Jelliffe, R W; Schumitzky, A.; Van Guilder, M.; Liu, M.; Hu, L.; Maire, P.; Gomis, P.; Barbaut, X. and Tahani, B. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. www 

1992

  1. Maire, P.H.; Barbaut, X. and Jelliffe, R W Antibiotic dose adjustment in renal insufficiency. In The Lancet, 340 (8833): 1478-9-author reply 1480-1, 1992.
  2. Kisor, D.F.; Watling, S.M.; Zarowitz, B.J. and Jelliffe, R W Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm. In Clinical Pharmacokinetics, 23 (1): 62-68, 1992.
  3. Jelliffe, R W; Schumitzky, A. and Van Guilder, M. Nonpharmacokinetic clinical factors affecting aminoglycoside therapeutic precision. In Drug Investigation, 4 (1): 20-29, 1992. doi 
  4. Bayard, D.S. Reduced complexity dynamic programming based on policy iteration. In Journal of Mathematical Analysis and Applications, 170 (1): 75-103, 1992.
  5. Schumitzky, A. Nonparametric Population Modeling. In Proceedings of the Western Simulation Multiconference, Simulation in Healthcare: 57-64, 1992.

1991

  1. Jelliffe, R W; Iglesias, T.; Hurst, A.K.; Foo, K.A. and Rodriguez, J. Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies. In Clinical Pharmacokinetics, 21 (6): 461-478, 1991. doi 
  2. Dodge, W.F.; Jelliffe, R W; Richardson, C.J.; McCleery, R.A.; Hokanson, J.A. and Snodgrass, W.R. Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. In Clinical Pharmacology and Therapeutics, 50 (1): 25-31, 1991.
  3. Moreira, C A Jr; Moreira, A.T.; Armstrong, D.K.; Jelliffe, R W; Woodford, C.C.; Liggett, P.E. and Trousdale, M.D. In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. In Acta Ophthalmologica, 69 (1): 50-56, 1991.
  4. Moreira, C A Jr; Armstrong, D.K.; Jelliffe, R W; Moreira, A.T.; Woodford, C.C.; Liggett, P.E. and Trousdale, M.D. Sodium hyaluronate as a carrier for intravitreal gentamicin. An experimental study. In Acta Ophthalmologica, 69 (1): 45-49, 1991.
  5. Schumitzky, A. Nonparametric EM Algorithms for Estimating Prior Distributions. In Applied Math and Computation, 45: 141-157, 1991.
  6. Bayard, D.S. A forward method for optimal stochastic nonlinear and adaptive control. In Automatic Control, IEEE Transactions, 36 (9): 1046-1053, 1991.
  7. Jelliffe, R W The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. In Proceedings of the Annual Symposium of Computer Applications in Medical Care: 922-924, 1991.

1990

  1. Hurst, A.K.; Yoshinaga, M.A.; Mitani, G.H.; Foo, K.A.; Jelliffe, R W and Harrison, E.C. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. In Antimicrobial Agents and Chemotherapy, 34 (6): 1165-1171, 1990.
  2. Jelliffe, R W and Schumitzky, A. Modeling, adaptive control, and optimal drug therapy. In Med.Prog.Technol., 16 (1-2): 95-110, 1990.

1987

  1. Chizeck, H.J.; Jelliffe, R W and Cheung, P.W. Automatic regulation for administration of therapeutic agents. In IEEE Trans.Biomed.Eng, 34 (8): 565-566, 1987.
  2. Jelliffe, R W Clinical applications of pharmacokinetics and adaptive control. In IEEE Trans.Biomed.Eng, 34 (8): 624-632, 1987.
  3. Jelliffe, R W Drug-receptor relationships, selection of therapeutic goals, and adaptive control of pharmacokinetic systems. In Fed.Proc., 46 (8): 2494-2501, 1987.
  4. Hurst, A.K.; Iseri, K.T.; Gill, M.A.; Noguchi, J.K.; Gilman, T.M. and Jelliffe, R W Comparison of four methods for predicting serum gentamicin concentrations in surgical patients with perforated or gangrenous appendicitis. In Clin.Pharm., 6 (3): 234-238, 1987.

1985

  1. Bayard, D. S. and Eslami, M. Implicit dual control for general stochastic systems. In Optimal Control Applications and Methods, 6 (3): 265-279, 1985. doi 

1984

  1. Rodman, J H; Jelliffe, R W; Kolb, E.; Tuey, D.B.; de Guzman, M.F.; Wagers, P.W. and Haywood, L.J. Clinical studies with computer-assisted initial lidocaine therapy. In Archives of Internal Medicine, 144 (4): 703-709, 1984.
  2. Jelliffe, R W Digitalis therapy: simple formulas to plan and adjust dosage regimens. In MD Comput., 1 (2): 36-41, 65, 1984.

1983

  1. Jelliffe, R W Open-loop-feedback control of serum drug concentrations: pharmacokinetic approaches to drug therapy. In Med.Instrum., 17 (4): 267-273, 1983.
  2. Jelliffe, R W Computer-controlled administration of cardiovascular drugs. In Prog.Cardiovasc.Dis., 26 (1): 1-14, 1983.

1982

  1. Rodman, J H; Hurst, A.; Gaarder, T.; Cohen, J. and Jelliffe, R W N-Acetylprocainamide kinetics and clinical response during repeated dosing. In Clinical Pharmacology and Therapeutics, 32 (3): 378-386, 1982.

1980

  1. Haldimann, B; Healy, M; Jelliffe, R.; Goldstein, D A; Pattabhiraman, R and Massry, S G Effect of an oral dose of 25-hydroxyvitamin D3 on its blood levels in patients with the nephrotic syndrome. In The Journal of clinical endocrinology and metabolism, 50 (3): 470-474, 1980. doi 
  2. Jelliffe, R W Electrolytes and cardiac arrhythmias. In Crit Care Update., 7 (1): 5-11, 1980.

1974

  1. Jelliffe, R W and Brooker, G. A nomogram for digoxin therapy. In American Journal of Medicine, 57 (1): 63-68, 1974.
  2. Goicoechea, F.J. and Jelliffe, R W Computerized dosage regimens for highly toxic drugs. In American Journal of Hospital Pharmacy, 31 (1): 67-71, 1974.

1973

  1. Jelliffe, R W Editorial: Quantitative aspects of clinical judgment. In American Journal of Medicine, 55 (3): 431-433, 1973.
  2. Jelliffe, R W Letter: Creatinine clearance: bedside estimate. In Annals of Internal Medicine, 79 (4): 604-605, 1973.
  3. Jelliffe, R W Planning drug doses for patients. In Dent.Dimens., 7 (3): 6-7, 1973.
  4. Goicoechea, F.J.; Bischel, M.D. and Jelliffe, R W Kinetics of procainamide in anuric patients undergoing chronic hemodialysis. In Proc.Clin.Dial.Transplant.Forum, 3: 92-95, 1973.

1972

  1. Jelliffe, R W; Buell, J. and Kalaba, R. Reducation of digitalis toxicity by computer-assisted glycoside dosage regimens. In Annals of Internal Medicine, 77 (6): 891-906, 1972.
  2. Jelliffe, R W and Ivler, D. Gentamicin and kanamycin nomograms. In Annals of Internal Medicine, 77 (3): 480-481, 1972.
  3. Jelliffe, R W; Buell, J. and Kalaba, R. Reduction of digitalis toxicity by computer-assisted glycoside dosage regimens. In Annals of Internal Medicine, 77 (6): 891-906, 1972.
  4. Brooker, G. and Jelliffe, R W Serum cardiac glycoside assay based upon displacement of 3 H-ouabain from Na-K ATPase. In Circulation, 45 (1): 20-36, 1972.

1971

  1. Jelliffe, R W Estimation of creatinine clearance when urine cannot be collected. In The Lancet, 1 (7706): 975-976, 1971.
  2. Jelliffe, R W Factors to consider in planning digoxin therapy. In Journal of Chronic Diseases, 24 (7): 407-416, 1971.
  3. Jelliffe, R W and Jelliffe, S.M. Estimation of creatinine clearance from changing serum-creatinine levels. In Lancet, 2 (7726): 710, 1971.

1970

  1. Jelliffe, R W; Buell, J.; Kalaba, R.; Sridhar, R; Rockwell, R. and Wagner, J.G. An improved method of digitoxin therapy. In Annals of Internal Medicine, 72 (4): 453-464, 1970.
  2. Jelliffe, RW; Buell, J.; Kalaba, R. and Sridhar, R A computer program for digitalis dosage regimens. In Mathematical Biosciences, 9: 179-193, 1970.
  3. Jelliffe, R W An improved method for replacing one digitalis glycoside with another. In Med.Times, 98 (1): 105-117, 1970.

1969

  1. Jelliffe, R W Common medical causes of headache. In J.Hosp.Dent.Pract., 3 (4): 83-85, 1969.
  2. Jelliffe, R W Administration of digoxin. In Dis.Chest, 56 (1): 56-60, 1969.
  3. Jelliffe, R W; Hill, D.; Tatter, D. and Lewis, E Death from weight-control pills. A case report with objective postmortem confirmation. In JAMA : The Journal of the American Medical Association, 208 (10): 1843-1847, 1969.
  4. Jelliffe, R W and Stephenson, R.G. A fluorometric determination of myocardial digoxin at autopsy, with identification of digitalis leaf, digitoxin, and gitoxin. In American Journal of Clinical Pathology, 51 (3): 347-357, 1969.

1968

  1. Jelliffe, R W An improved method of digoxin therapy. In Annals of Internal Medicine, 69 (4): 703-717, 1968.

1967

  1. Jelliffe, R. W A mathematical analysis of digitalis kinetics in patients with normal and reduced renal function. In Mathematical Biosciences, 1 (2): 305-325, 1967. doi 
  2. Jelliffe, R W Autopsy verification of suicide by digitalis. Report of a case, with successful chemical identification of digitalis glycosides in gastric contents. In American Journal of Clinical Pathology, 47 (2): 180-185, 1967.